Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

British Journal of Cancer

Volumn 112, Issue 9, 2015, Pages 1421-1427

  Homet Moreno, B ^a   Ribas, A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BLADDER CANCER; CANCER THERAPY; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LONG TERM CARE; METASTATIC MELANOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84928760665     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.124     Document Type: Article

References (65)

1. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, Mcdermott DF, Knox JJ, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DY, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Hammers HH. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRC) [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
2. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. (2011). Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-Associated T cells. Clin Cancer Res 17: 4232-4244
3. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma. N Engl J Med 372: 311-319
4. Armand P, Ansell SM, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, Timmerman J, Borrello I, Gutierrez M, Scott EC, Cattry D, Chapuy B, Ligon AH, Rodig SJ, Zhu L, Grosso JF, Kim SY, Shipp MA. (2014). Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract Am Soc Hematol (Meeting Abstracts) 289
5. Atkins MB, Kudchadkar RR, Sznol M, Mcdermott MD, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, Slingluff CL, Ernstoff MS, Fay JW, Friedlander PA, Gajewski T, Zarour HM, Rotem-Yehudar R, Sosman JA. (2014). Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
6. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A. (2008). Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051
7. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, Sankar V, Ahlers CM, Wigginton JM, Kollia G, Gupta AK, Gettinge SN. (2013). Survival and long-Term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer [abstract]. J Clin Oncol (Meeting Abstracts) 31: abstract 8030
8. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, Robbins PB, Vasselli J, Ibrahim RA, Antonia SJ. (2014). Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
9. Brahmer JR, Tykodi SS, Chow LQM, Hwu W, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465
10. Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, Mcdermott DF, Delord J-P, Rhee IP, Mokatrin A, Kowanetz M, Funke RP, Fine GD, Powles T. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRC) [abstract]. J Clin Oncol (Meeting Abstracts) 31: abstract 4505
11. Curran MA, Montalvo W, Yagita H, Allison JP. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107: 4275-4280
12. Ding H, Wu X, Gao W. (2005). PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol 115: 184-191
13. Egen JG, Allison JP. (2002). Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16: 23-35
14. Fairman D, Narwal R, Liang M, Robbins PB, Schneider A, Chavez C, Lu H, Pak M, Blake-Haskins A, Vasselli J, Ibrahim RA, Shalabi AM, Roskos L. (2014). Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
15. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015-3029
16. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034
17. Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, Goldman JW, Hui R, Soria J, Gangadhar TC, Sun J, Patnaik A, Gubens MA, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson ME, Gandhi L. (2014). Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCL) [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
18. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144
19. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, Boasberg PD, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen DS, Hodi FS (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [abstract]. J Clin Oncol (Meeting Abstracts) 31: abstract 9010
20. Hammers H, Plimack E, Infante J, Ernstoff M, Rini B, Mcdermott D, Albiruni R, Razak A, Pal S, Voss M, Sharma P, Kollmannsberger C, Heng D, Spratlin J, Shen Y, Kurland J, Gagnier G, Amin A. (2014). Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRC). J Clin Oncol 32: 5s
21. Heery CR, Coyne GS, Madan RA, Schlom A, Heydebreck A, Cuillerot J, Sabzevari H, Gulley JL. (2014). Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
22. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J, Hamid O, Powderly JD, Burris HA, Mokatrin A, Kowanetz M, Leabman M, Anderson M, Chen DS, Hodi FS. (2013). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [abstract]. J Clin Oncol (Meeting Abstracts) 31: abstract 3000
23. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, Mcdermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567
24. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. (2010). Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757-1766
25. Hodi FS, Oday SJ, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Van Den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
26. Hodi FS, Sznol M, Kluger HM, Mcdermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Leming PD EJL, Taube JM, Anders R, Horak CE, Kollia G, Gupta AK, Sosman JA. (2014). Long-Term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5
27. Ishida Y, Agata Y, Shibahara K, Honjo T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895
28. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, Weber JS, Dronca RS, Patnaik A, Zarour HM, Dolled-Filhart M, Lunceford J, Emancipator K, Ebbinghaus S, Kang SP, Hwu W. (2014). Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
29. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. (2006). Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895
30. Korman AJ, Peggs KS, Allison JP. (2006). Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297-339
31. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N. (2009). PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23: 375-382
32. Lenschow DJ, Walunas TL, Bluestone JA. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258
33. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. (1994). Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1: 793-801
34. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. (2014). PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2: 361-370
35. Moskowitz CH, Ribrag V, Michot J, Martinelli G, Zinzani PL, Gutierrez M, De Maeyer G, Jacob AG, Giallella K, Anderson JW, Derosier MD, Wang J, Yang Z, Rubin R, Rose S, Shipp MA, Armand P (2014) 290 PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) [abstract]. Am Soc Hematol (Meeting Abstracts) 290
36. Motzer R, Rini B, Mcdermott D, Redman B, Kuzel T, Harrison M, Ua V, Drabkin H, George S, Logan T, Margolin K, Plimack E, Waxman I, Lambert A, Hj H (2014) Nivolumab for metastatic renal cell carcinoma (mRC): Results of a randomized, dose-ranging phase II trial. J Clin Oncol (Meeting Abstracts) 32: 5s
37. Motzer RJ, Rini BI, Mcdermott DV, Redman BG, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Waxman I, Lambert A, Hammers HJ (2014) Nivolumab for metastatic renal cell carcinoma (mRC): results of a randomized, doseranging phase II trial [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
38. Okazaki T, Honjo T. (2007). PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813-824
39. Pardoll DM. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264
40. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13: 84-88
41. Pleasance ED, Stephens PJ, Omeara S, Mcbride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordonez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, Mclaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, Mckernan KJ, Stratton MR, Futreal PA, Campbell PJ. (2010). A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190
42. Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Zambrano CC, Bellmunt J, Burris HA, Teng SM, Shen X, Koeppen H, Hegde PS, Chen DS, Petrylak DP. (2014). Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UB) [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
43. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu W, Gangadhar TC, Patnaik A, Joshua AM, Hersey P, Weber JS, Dronca RS, Zarour HM, Gergich K, Li X, Iannone R, Kang SP, Ebbinghaus S, Robert C (2014) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
44. Ribas A, Tumeh PC. (2014). The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20: 4982-4984
45. Ribas A, Wolchok JD, Robert C, Kefford K, Hamid O, Daud A, Hwu WJ, Weber JS, Joshua AM, Gangadhar TC, Patnaik A, Hersey P, Dronca R, Zarour H, Gergich K, Lindia JA, Giannotti M, Li X, Ebbinghaus S, Kang SP, Hodi FS (2014) Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (pembro, MK-3475) in 411 patients (pts) with melanoma (MEL) [abstract]. Soc Melanoma Res (Meeting Abstracts
46. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH, Linsley PS. (2002). Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA 99: 11790-11795
47. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109-1117
48. Robert C, Thomas L, Bondarenko I, Oday S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller Jr. WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526
49. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. (2004). Cytotoxic T lymphocyte-Associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27: 478-479
50. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, Leblanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. (2003). Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851-862
51. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J, Khleif S. (2014). Preliminary data from a multi-Arm expansion study of MEDI4736, an anti-PD-L1 antibody [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s
52. Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, Cruz C, Conkling P, Cassier PA, Antonia SJ, Burris HA, Fine GD, Mokatrin A, Kowanetz M, Shen X, Chen DS, Soria J. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCL) [abstract]. J Clin Oncol (Meeting Abstracts) 31: abstract 8008
53. Taube JM, Anders RA, Young GD, Xu H, Sharma R, Mcmiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. (2012). Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra137
54. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prevost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L. (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 71: 5393-5399
55. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-Tumor immunity. Curr Opin Immunol 24: 207-212
56. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, PD Leming, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, Mcmiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, Mcdonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454
57. Topalian SL, Sznol M, Mcdermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. (2014). Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030
58. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571
59. Weber JS, Minor DR, Dangelo S, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Grob J, Lao C, Linette G, Grossman K, Hassel J, Lorigan P, Maio M, Snolz M, Lambert A, Yang A, Larkin J. (2014). A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigators choice chemotherapy (IC) in patients with advanced melanoma after prior anti-CTLA-4 therapy [abstract]. Eur Soc Med Oncol Congr (Meeting Abstracts) 728
60. Westin J, Chu F, Foglietta M, Rotem-Yehudar R, Neelapu S. (2010). Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol (Meeting Abstracts) 28: 15s
61. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. (2009). B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114: 2149-2158
62. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. (2008). CTLA-4 control over Foxp3 regulatory T cell function. Science 322: 271-275
63. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133
64. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D. (2008). Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 39: 1050-1058
65. Zou W, Chen L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477